Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1617 participants.

Also called NCT03400800

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,617 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03400800
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Czechia, Germany, Hungary, Poland, South Africa, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03400800. Randomized; double masking; primary purpose treatment. Start 2017-11-01 (actual); primary completion 2019-07-31 (actual). Results posted on 2020-08-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
Acronym
ORION-11
Condition
ASCVD
Condition
Risk Factor, Cardiovascular
Condition
Elevated Cholesterol
Intervention (Drug)
Inclisiran Sodium
Intervention (Drug)
Placebo
Lead sponsor
The Medicines Company (class: industry)

Record details

Record id
cardio:ct-nct03400800
Content hash
b6a6017a5f01ecef870eeb77d56e9bb10e567d18b73392da45909d31147133de